Professor Solomon P. Wasser and Medicinal Mushroom Science, with Special Attention to the Problems of Mycotherapy in Oncology.

Abstract

This article is dedicated to the 75th anniversary of Solomon P. Wasser and discusses the challenges within the research direction he founded with Professors T. Mizuno, S.T. Chang, and other colleagues, known as medicinal mushroom science. This research organically grows out of taxonomic studies, since understanding of the classification system leads to greater ability to make forecasts and predictions in the practical field as well as to increase knowledge of close relationships between organisms, allowing greater eeconomic organization within the search and screening for new practically significant organisms. Through the efforts of Professors Wasser, Mizuno, and Chang, the International Journal of Medicinal Mushrooms (IJMM) was created, combining the efforts of physicians using mushroom raw materials as an auxiliary tool and specialists in fungal biotechnology. In this work, the basic prerequisites for cancer mycotherapy are described, based on data on the mechanism of action of fungal metabolites on cancer targets. A large section of this report is devoted to a review of evidence-based medicine tools and an overview of their use among teams of Chinese researchers. It has been shown that the main recipients of mycotherapy, as well as other types of immunotherapies, are patients with stage 3 cancer who have undergone surgery to remove the primary tumor node and are undergoing chemotherapy; for these patients, their immune status must be increased, and the immune system requires a periodic rebooting. In this respect, Dectin stimulation using fungal glucans is comparable to cytokine therapy and can be characterized as an "endogenous cytokine therapy." The results of the combined treatment at this stage are to be quantified using evidence-based medicine tools, for which we recommend including the consumption of mushroom extracts in the patient questionnaire. This article also discusses challenges in the pharmacokinetics of β-glucans and triterpenoids.